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Abstract: 
β-thalassemia constitutes a major public health problem in the UAE and shows one of 
the highest carrier frequencies of β-thalassemia in the Gulf region. In spite of the 
advances in thalassemia treatment and increased survival rates, patients still suffer 
disease complications and significant burden from chronic treatment with transfusions 
and chelation. Furthermore, it is rather harder for them to face life challenges. Hence, 
the preservation of good quality of life is one of the major targets in clinical management 
of thalassemia patients which was assessed and highlighted in different studies. It is 
believed that these assessments provide complementary clinical information to help the 
hematologists in the holistic evaluation of the patient's health status. 
Methods: A cross-sectional study was conducted among children and adolescents with 
thalassemia who received treatment in Saqr Hospital in UAE. Quality of life assessment 
was performed using the Quality of Life SF-36 questionnaire. The other instrument was 
a clinical record form including the demographics of the patients and clinical information 
about the disease history and lab findings pertaining to blood transfusion, blood indexes 
and medications. All patients signed a consent form prior to participating in the study. 
The results were compared to similar study done in the same center three years earlier. 
Results: Out of 25 patients recruited, more patients expressed better health than one 
year ago in our study (56%) than the previous study (36%). Physical Functioning was 
nearly the same in both studies while Role-Physical, Body Pain and General Health, 
Vitality, Social functioning, Role-emotional, Mental Health, and mental composite 
summary were higher in the current study. The average serum ferritin of the patients 
was 1473.358 ng/mL. 
Conclusion: Quality of life in thalassemic patients in our study done in 2014 showed 
improvement when compared to the results obtained in the same center three years 
ago. The domains mostly affected were the role-physical and role-emotional. This 
improvement in the quality of the patient life can be explained by changing parenteral to 
oral iron chelation therapy and the continuous health education programs. Quality of life 
assessment studies are warranted to increase the understanding of the thalassemia 
impact on the patients and to provide the necessary patient and family support.  
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Abbreviations and definitions 
ANOVA               Analysis of Variance                             
BP                      Body Pain 
CBCL              Child Behavior Check List 
DFE                 Desferoxamine 
DFO                 Deferoxamine 
DoH                  Declaration of Helsinki   
EPIC study     Iron Chelation with Exjade study 
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Hb                      Hemoglobin 
HEED             Health Economic Evaluation Database 
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MDS                 Myelodysplasias 
MH                   Mental Health 
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MOS Medical  Outcomes  Study 
MRI                     Magnetic Resonant Imaging 
PCS                    The physical composite scores 
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PedsQLTM  
SCD  
Sickle Cell Disease Module for pediatric patients with sickle cell 
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PF                      Physical Functioning 
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QOL                The Quality of Life 
RAKHMSU    Ras Al Khaimah Medical And Health Sciences University 
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SCD               sickle cell disease 
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SF-36             Short-Form Health Survey (Quality of Life questionnaire) 
SICT                satisfaction with iron chelation therapy 
SPSS                 Statistical Package for the Social Sciences 
STQOLI            self-administered Specific Thalassemia Quality of Life     
UAE               United Arab Emirates 
VT                     Vitality 
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1. Introduction and background: 
1.1. Thalassemia  
Normal hemoglobin A consists of two α and two β chains. The globin gene clusters are 
present on chromosome 16 while the β gene clusters are present on chromosome 11. 
Thalassemias are autosomal recessive disorders (1). In Beta thalassemia, beta globin 
chain synthesis is decreased resulting in an excess of alpha chains. This leads to 
increased synthesis of the hemoglobins without beta chains [e.g. Hb-F (alpha2 
gamma2), Hb-A2 (alpha2 delta2)]. Left over free alpha chains form tetramers (alpha4), 
which are very insoluble and precipitate in red cells leading to increased fragility and 
early red cell death (2). 
The main symptom of beta thalassemia major is severe anemia due to ineffective 
erythropoeisis, haemolysis and hypersplenism. Extramedullary erythrocyte precursor’s 
destruction instigates a decrease in erythrocyte release into the blood stream. 
Hemolytic activity in the reticulo-endothelial systems (RES) increases due to the 
destruction of inclusion bodies containing mature erythrocytes, leading to hyperplasia of 
the RES, erythroid system, and extramedullary hemopoeisis. Extramedullary 
hemopoeisis occurs in the liver and spleen, initiating hepatomegaly and 
splenomegaly(3). 
1.2. Epidemiology of thalassemia: 
Thalassemia is a growing global public health problem with an estimated 900,000 births 
of clinically significant thalassemia disorders expected to occur in the next 20 years (4). 
Men and women are equally affected by thalassemia. The prevalence of thalassemia is 
4.4 of every 10,000 live births. The prevalence of globin variant in the world population 
9 
 
is 5%. However, the prevalence of α- or β-thalassemia trait in the world population is 1.7% 
(Figure1). Globally, an estimated 15 million people have thalassemia. Thalassemia trait 
is more prevalent affecting 5-30% of people from the following ethnic groups:  
 
Figure1: Epidemiology of thalassemia: carrier frequencies of thalassemia alleles (%) (5) 
 
1. Alpha thalassemia is more common in: African, Middle Eastern, East Indian, 
Southeast Asian (Vietnamese, Laotian, Thai, Singaporean, Filipino, Cambodian, 
Malaysian, Burmese and Indonesian), Chinese and Occasionally Mediterranean 
(Italian and Greek). The most severe form of alpha thalassemia causes fetal or 
newborn death.  
2. Beta thalassemia is more common in: Mediterranean (Italian and Greek), Iranian, 
African, Southeast Asian and Chinese. 
3. E Beta thalassemia is more common in Southeast Asian (Cambodian, Vietnamese 
and Thai).  
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4. Sickle Beta Thalassemia is more common in Mediterranean (Italian, Greek and Turk) 
people.  
β-thalassemia and malaria: The prevalence of β-thalassemia is highest in areas where 
malaria is (or was) endemic (Figure 2). Similar to β-thalassemia, α-thalassemia is 
prevalent in tropical and subtropical regions, where malaria was or still is endemic. It is 
thought that carriers of hemoglobinopathies have a degree of protection against malaria, 
although the mechanism underlying this protection is unknown. 
 
 
Figure 2: Distribution of Non Transfusion Dependent Thalassemia   (6) 
According to the previous figures (1 and 2) and the ethnic distribution, it can be inferred 
that thalassemia represents a serious public health problem throughout the 
Mediterranean region, the Middle East and the Indian subcontinent, as well as in 
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Southeast Asia(7). United Arab Emirates (UAE) is one of the countries falling under the 
high risk regions where surveys have shown that the UAE exhibits one of the highest 
carrier frequencies of β-thalassemia in the Gulf region. This was detected by conducting 
DNA studies on over 400 consecutive UAE National newborns and nearly 2000 adult 
college students and 800 randomly selected Emiratis who demonstrated that the 
frequency of β-globin gene defect including the β-thal, βS gene and abnormal 
hemoglobins is estimated at 8.5%, which is one of the highest in the Gulf Region. 
During 1989-2004, more than 850 patients have been registered at the Dubai Genetics 
and Thalassemia center(8).  
1.3. Thalassemia treatment and complications:  
Although medical advances in the treatment of thalassemia have led to increased 
survival rates, patients still suffer disease complications. It was found that the life 
expectancy of thalassemic patients has dramatically increased to reach into 4th and 5th 
decades of life with the combination of regular blood transfusions and chelation therapy. 
However, the frequent blood transfusion has also led to iron overload with many 
complications including endocrinopathies, behavioral and neurotic problems, growth 
failure, cardiovascular problems, liver disease, gonadal dysfunction and delayed 
puberty(9, 10). It was also found that thalassemic children are1.6-fold higher than the 
healthy children concerning behavioral abnormality (11). 
The detrimental effect of iron overload requires Iron Chelation Therapy (ICT) in order to 
reduce the excess iron load that is not eliminated properly. Desferoxamine (DFE), a 
parenteral drug used widely as ICT, has been employed in the treatment of beta 
thalassemia for nearly forty years and has shown to be effective in reducing the hepatic 
12 
 
and extra-hepatic adverse effects, particularly myocardial toxicity. Oral chelators such 
as Deferasirox are available also yet are much more expensive than the traditional 
ICT’s(12).  
The effect of thalassemia, its complications and chronic treatment options like 
transfusion and chelation can extend further to impact the patient’s quality of life 
adversely (13, 14). It is important to assess the impact of this chronic disease on a 
patient’s everyday life, thus a scale was used for that purpose; the “Health Related 
Quality of Life” (HRQOL). HRQOL refers to the patient’s perception of their physical and 
mental health and it helps to compare different groups of patients and measure the 
effect of an intervention(15).  
The Quality of Life (QOL) of individuals with thalassemia major is influenced by many 
factors such as the impact of the diagnosis and treatment, having a chronic condition, 
appearance, treatment components like frequent hospital visits for transfusion, nightly 
subcutaneous infusions, delayed or absent sexual development, complications of the 
disease and therapeutic interventions and uncertainties about the future (16). Various 
studies have discussed the social, cultural and educational difficulties faced by 
thalassemia patients. The patients QOL is mainly disturbed in the domains of education 
and sports where most thalassemics were not satisfied with their body image. 
Furthermore, high level of anxiety was expressed about their future health and 
education being dependent largely on their parents for financial and emotional support 
(17). 
The thesis is structured as a monograph. Chapter two discusses the relevant literature 
review about the main topic. Chapter three covers the methodology used according to 
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the theoretical basis and the practical implementation of data collection and data 
analyses along with ethical considerations. The results obtained are presented in 
chapter four. In chapter five, the results are discussed as well as methodological 
strengths and limitations. Finally, the thesis ends up with a conclusion and 
recommendation for practice and future research. 
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2. Literature review:  
 
Our current study is a follow up study preceded by a similar study done in 2011. To 
review the relevant literature Pub med, Medline and google scholar databases were 
searched by using these keywords; Quality of life, thalassemia major, SF-36, 
thalassemia, quality of life- instruments – validation, thalassemia - quality of life - iron 
chelation. The search result of relevant literature are considered and presented in this 
chapter. The rationale and research objectives are stated at the end.  
In the beginning, it is worthy to mention that the therapeutic options for the treatment of 
thalassemia had resulted in the prolongation of survival rates. However, the continuous 
need for frequent blood transfusions and iron chelation therapy added more 
psychological and social impact on these patients. This would affect their quality of life 
and represents a crucial aspect of the patient’s suffering that should not be neglected 
throughout the process of disease management. Several studies have been 
investigating instruments to assess the QOL in thalassemic patients to help in a sound 
assessment of the therapeutic benefit both physically and mentally.  
 
2.1. Quality of life assessment instruments: 
The health-related quality of life (HRQOL) has been widely used in the assessment of 
the quality of life in general and in patients with chronic diseases in specific. It has 
evolved since the 1980s to include health aspects; either physical or mental. The short 
form (SF-36) measures, which are part of the HRQOL, are now used by the Health care 
authorities in the United States of America (USA) to help evaluate the quality of care in 
managed care plans and other health care applications. The questionnaire underwent 
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extensive validation in the early 1990s by researchers and health care and prevention 
programs to consider it as a reliable set of measures in further studies (18).  
Other researchers tried to adopt new instruments for the same purpose as in a study 
done in USA and UK to evaluate the reliability and validity of a new instrument used to 
assess satisfaction with iron chelation therapy (SICT) (19). The results showed that 
SICT was reliable and valid and it can be used in clinical trials.  
  In addition, an instrument was developed and validated in the form of interview which 
was found to be brief, clinically relevant, multidimensional to assess pain burden among 
children and adolescents with sickle cell disease (SCD). It was called “Sickle Cell 
Disease Pain Burden Interview-Youth” (SCPBI-Y). SCPBI-Y interview was found also to 
be useful in different clinical settings in children and adolescents  (20).  
  PedsQLTM is another assessment tool studied in a qualitative study to develop the 
items and support the content validity. It stands for the Sickle Cell Disease Module for 
pediatric patients with sickle cell disease (SCD). The qualitative research was done on 
several phases in the form of Individual cognitive interviews. The interviews used both 
think aloud and cognitive debriefing techniques to assess the different items of the 
module. Interviews were conducted with patients and parents and the opinions of 
experts were put in consideration when constructing the module. It comprises six 
domains, consisting of 48 items to measure Pain Intensity/Location (9 items), Pain 
Interference (11 items), Worry (7 items), Emotions (3 items), Disease 
Symptoms/Treatment (12 items), and Communication (6 items). 
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The validity of PedsQLTM SCD was confirmed by several researches through field work 
in different sites in the world (21). Henceforth, the PedsQLTM SCD Module was 
accepted as a research instrument and it can be used in the assessment of SCD-
specific health-related quality of life in clinical research and practice especially if 
combined with the PedsQLTM Multidimensional Fatigue Scale (22).  
Similarly, an Iranian experimental study was done to discuss the effect of family-
centered empowerment model on quality of life of school-aged children 6-12 years with 
thalassemia major. The Data collected were demographic and general quality of life 
questionnaires in children, these data covered physical, emotional and social aspects in 
addition to school functions. The questionnaires were used after determining the 
content validity and reliability by internal correlation method, quality of life was 
measured 1.5 months after the intervention.  The average quality of life of thalassemic 
children after the intervention was significantly higher than before the intervention. Yet 
the questionnaire was not repeated in other studies to evaluate its effectiveness (23).  
Considering the adult patients, Greek researchers carried out a study to develop a self-
administered Specific Thalassemia Quality of Life Instrument (STQOLI) for adult 
patients according to psychometric measures. To develop (STQOLI), first, a qualitative 
study was done to generate items and identify domains using the critical analysis 
incident technique and a literature review, this qualitative study involved both patients 
and experts, then quantitative validation was carried out to select items, identify 
dimensions, and measure reliability and internal and concurrent validity, finally the 
questionnaire had 41 items comprising four main domains and one global item about 
general health. This instrument shows validity for HRQOL for patients with thalassemia 
17 
 
but still more research is needed to understand more about the universal properties of 
the questionnaire (24).  
 However, the Quality of Life SF-36 questionnaire is still considered more advanced 
instrument covering different aspects of QOL, used universally and can be applied for 
different age groups.  
2.2. Thalassemia and Quality of life: 
 The literature showed studies about variable aspects of the disease progress in the 
patient’s life ranging from assessing the impact of the disease per se, passing through 
the patient perception with regard to social and mental effects, ending with the 
complications or benefits of therapeutic measures and future solutions to find less 
invasive or even permanent remedies.    
A study in India concluded that thalassemia can be considered nationally as a disability 
necessitating the involvement of different authorities as it was found that the disease is 
extremely stressful, and patients face a variety of physical, psychological and social 
problems. The findings also showed that cultural and educational backgrounds play a 
major role in illness experiences (25). 
Not far from the previous study, a cross-sectional study assessed the quality of life 
(QOL) among thalassaemic children aged 4 to 12 years during the year 2007-08 in 
Pakistan, showed that parents were highly concerned about QOL aspects in their 
affected children. However, this study covered only thalassemic children; it did not 
involve adults (26).  
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Another study showed that the QOL of Thai children with thalassemia was significantly  
affected by the patient’s age, age at onset of anaemia and age at first transfusion, pre-
transfusion haemoglobin (Hb) level, receiving a blood transfusion during the previous 
three months and disease severity. It was found also that iron chelation therapy had 
negative effect of school functioning subscale (27). However, the study involved only 
sick children without determining the severity of the disease and the PedsQL™ 4.0 
Generic Core Scale was used, limiting the study to children age only.  
Moving to the Middle East, the SF-36' questionnaire was used to assess the QOL in 
patients in Saudi Arabia but it was on sickle cell disease (SCD). It showed obvious 
deterioration of QOL especially in role physical, general health and bodily pain domains 
irrespective of the gender. Notably, females with SCD showed more deterioration in 
emotional wellbeing. Worse deterioration was seen in patients with disease 
complications in the physical, general health and emotional wellbeing domains. The 
HRQOL scores were negatively affected by advanced age, female gender, rural areas 
residency, low socioeconomic status, presence of disease complications, multiple 
hospital admissions as revealed by multivariate regression analysis. The findings 
augmented the researchers’ recommendation to emphasize and increase the public 
awareness about the national program for the premarital survey to screen for 
hematological diseases like SCD and thalassemia which is carried out in Saudi Arabia 
(28). It is worthy to mention that these findings are comparable to the factors which 
affect the QOL of thalassemic patients seen in other studies.  
Similarly, school functioning and the physical functioning domains in the HRQOL and 
the Pediatric Quality of Life Inventory assessment showed the lowest mean score when 
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applied to thalassemic children in Jordan. They were related also to the socio-
demographic and clinical data and a comparison was conducted with healthy children to 
verify the results (29).  
In South America, the sociodemographic characters and the effect of the disease on the 
quality of life of SCD Brazilian adult patients were investigated by using SF-36 
questionnaire. The results showed that the disease decreased the working capacity of 
individuals with low incomes and the resultant inaccessibility to healthcare services 
causing noticeable impairment of QOL(30).  
Far away from their countries of origin, the thalassemic immigrants from Southeast 
Asian and Asian Indian origin were surveyed in the USA, namely those who were 
affected by thalassemia major and living in an urban area. The study discussed the 
sociocultural and socioeconomic problems suffered by them and it was found that the 
emotional and social aspects were maximally disturbed especially for the thalassemic 
children and their parents. This painful effect was found to be exaggerated by the 
disease severity and certain cultural believes, upon which the researchers 
recommended to do more investigations to develop initiatives to improve their QOL(31). 
2.3. Thalassemia treatment and its impact: 
Regarding the effects of the therapeutic interventions of thalassemia on the patients’ 
QOL, several studies can be found to assess the impact of iron overload and iron 
chelation therapy and some researches went beyond that to study possible permanent 
treatment modalities which seem to be promising to provide better QOL.  
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Deferoxamine (DFO), most commonly delivered by continuous subcutaneous infusion 
over 8 to 12 hours a day, is the oldest available form of ICT used by patients with 
transfusion-dependent disorders. Prior research, albeit in small sample sizes, has 
indicated significant deficits in health related quality of life (HRQOL) among patients 
receiving DFO for the treatment of transfusion-dependent iron overload, compared to 
values from age-matched normative populations (32,33). In particular, the time-
consuming nature of DFO regimens and side effects associated with this form of ICT 
(including local site reactions) (34-36) can have a detrimental impact on numerous 
facets of patients’ lives; including work, social activities, sex life, sleep and emotional 
well-being (37). As a result, patient satisfaction with DFO treatment regimens was low 
and suboptimal adherence was common among patients (32, 33). Improvements in ICT 
administration convenience and tolerability are expected to improve patient’s 
satisfaction with ICT and HRQOL, thus promoting adherence to ICT regimens and 
potentially reducing iron overload-related morbidity/mortality and associated healthcare 
costs (38, 39).  
The other ICT, Deferasirox (Exjade), was first approved in 2005 and nowadays is the 
most widely prescribed for patients as it is orally administered (40). Deferasirox has 
been shown to be effective and generally well-tolerated for the treatment of iron 
overload in β-thalassemia and Myelodysplastic syndrome patients (41, 42). Findings 
from clinical trials comparing outcomes in patients with iron overload treated using 
deferasirox or DFO have also suggested the superiority of deferasirox in terms of 
treatment satisfaction and adherence (43, 44). However, additional research using 
validated patient-reported outcome (PRO) measures is needed in order to better 
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understand the added benefits of deferasirox over DFO in improving HRQOL and 
treatment satisfaction, adherence, and persistence among patients with transfusion-
dependent iron overload (41, 42).  
The superiority of oral chelators over injectable ICT was also proved in a cross-sectional 
study in Kerman city in Iran where the QOL was better in the former ICT in a group of 
patients suffering from thalassemia major and intermedia (45). The study was meant 
mainly for children and did not investigate the benefit in adult patients.  
Furthermore and regardless of the ICT medication used, it was found that delayed start 
of iron chelation therapy had negative effect on HRQOL thalassemia children and their 
parents originally coming from countries of the Middle East. The study which was 
conducted in Italy used the Pediatric Quality of Life Inventory (PedsQL) 4.0 as an 
instrument in a cross-sectional study from November 2007 to August 2008. The 
Questionnaire was completed by all patients and their parents with lower scores 
presented by the parents (46).  
 Yet, more research is needed to study the factors associated with HRQOL in children 
and adolescents with thalassemia to provide better understanding of these factors and 
hence, more suitable clinical, counseling, and social support programs or proactive care 
assistance can be offered to enhance treatment outcomes (44).  
More advances in the treatment of thalassemia were suggested by an Italian study 
stating that the prognosis for thalassemia major patients became "open-ended". The 
advances upon which the researchers built their recommendations are advances in red 
cell transfusion and the introduction of new ICT. More progresses are expected as well 
in the management of thalassemia with the possibility of bone marrow transplantation 
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using HLA-matched unrelated donors, gene therapy and improvement in iron chelation.  
This would improve survival and quality of life. The study recommended also that 
Western countries and economic organizations should spend more efforts to deliver 
high standard of management of thalassemia everywhere in the world (47). This will 
open the scope for future clinical studies to discuss the effect of the newer agents and 
modalities in improving the quality of life and life expectancy of thalassemia patients 
(48). 
2.4. Research objectives and rationale: 
The research work was done in response to the growing needs to assess the quality of 
life of this group of patients and to attain the benefits of the early detection of social and 
physical disturbances caused by thalassemia and its treatment. The main objectives 
were to study the impact of thalassemia disease on the physical and psychological 
activity of thalassemia patients, and to study the different clinical and therapeutic factors 
such as rate of blood transfusion, chelation therapy on physical and psychological well-
being of those patients. In addition, it was projected to compare the patients’ perception 
about the progress of the disease and QOL on two different occasions. 
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3. Methodology:  
 
In this chapter, the methodological design of our study is deliberated but this is 
preceded by a short account on the different qualitative and quantitative research 
methodologies. Then the cross sectional design, sample selection, location and 
population of this study are discussed, followed by data collection and SF-36 
questionnaire discussion. Lastly, the ethical considerations and data handling were 
elaborated.  
Research methodology can be qualitative or quantitative. The research question in 
qualitative type is to know why something is a problem or how it is perceived as a 
problem, and the participants views about the problem.(49) Hence, qualitative research 
is descriptive and interpretative, and seeks to understand the meaning of problem 
experiences of the participants.(50) 
On the other hand, Quantitative research methods are used to answer questions on 
quantifying size and distribution of a disease and to study the associations of a disease 
and another dependent variable.(49) 
Epidemiology studies are quantitative researches developed to investigate how an 
exposure affects a certain population focusing on factors influencing or determining the 
distribution of a disease.(51) In other words, the objectives of epidemiology studies are 
to identify etiology and influencing risk factors, the extent of the disease or the health 
status in a population, the natural history and prognosis of the disease, to evaluate 
interventions, and to provide the foundation for developing public health policies.(52) 
According to the design, the epidemiological studies can be divided into observational 
(Non-interventional) and experimental (interventional).  Observational  studies  include  
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exploratory, descriptive,  analytical,  ecological,  cross sectional,  case control  and  
cohort  studies.  Experimental  studies are interventional and include  randomized  
controlled  trials,  cluster  randomized  controlled  trials,  field  trials, and  community  
trials.(49, 52)   
3.1. Study design: 
Our study was a cross sectional study conducted among children and adolescents with 
thalassemia who received treatment at Saqr hospital, Ras Al Khaimah (RAK) – UAE. 
The cross sectional study design suits this study as this design is commonly used to 
describe the burden of the disease in the community and its distribution. It can be 
repeated to measure change in a population through data collection by questionnaire 
predominantly or by structured interview on more than one case at a single point of time 
with the possibility of detecting patterns of association between the collected variables. 
Furthermore, the cross sectional studies can be completed within short time with limited 
resources. 
Moreover, it allows collecting large amounts of data from a large number of people on 
wide variety of subjects, so the data can be used by researchers from various 
disciplines. Also cross-sectional research works well for exploratory studies to test a 
research topic prior to large scale studies. To do a cross sectional study, it is also 
feasible to do within the scope of a master thesis  both  regarding  the  obvious  time  
constraints,  and  the  limited  resources  available. However, the cross- sectional 
method can only reveal associations, no causative links.   
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3.2. Study instrument: Quality of life (QOL), (SF-36 questionnaire)  
In our study, quality of life assessment was performed using the Quality of Life SF-36 
questionnaire, the standard Forward-Backward procedure was applied to translate the 
SF-36 questionnaire from English to Arabic by a bilingual individual with some cultural 
adaptation. In addition to the Quality of Life SF-36 questionnaire, the other instrument 
was a clinical record form, this form consisted of questions concerning demographics of 
the patients (e.g., gender, age, etc.), and clinical information (e.g., onset of anemia, 
diagnosis, age at first transfusion, history of blood transfusion, hemoglobin (Hb) levels 
and other laboratory reports, complications, serum ferritin level, iron chelation treatment, 
etc.).  
3.3. Sample selection:  
3.3.1. Inclusion criteria: 
1- Patients diagnosed with thalassemia. 
2- Patients above 5 years of age.  
3.3.2. Exclusion criteria: 
1- Patients with severe clinical condition which may limit their ability to participate in the 
study. 
2- Patients unwilling to participate in the study 
3.4.  Location and population: 
Participants were recruited from Saqr Hospital in RAK Emirate in the UAE. We recruited 
patients above 5 years old as they can express their feelings while children below 5 
years cannot. Our participants are residents of RAK. The RAK Medical Zone oversees a 
number of hospitals and public medical centres as well as a range of specialized clinics 
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and pharmacies all over RAK. The most important health facilities in RAK are: Saqr 
Hospital, Obaidullah Hospital, Shaam Hospital, RAK Preventive Medical Center, Dental 
Center, RAK Rehabilitation Centre for Disabled with special needs and RAK centre for 
special needs.  
Our research was run by Ras Al Khaimah Medical and Health Sciences University 
(RAKHMSU). 
 
Figure 3: Saqr Hospital in RAK- UAE 
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Figure 4: Ras Al Khaimah Medical and Health Sciences University- RAK- UAE 
 
3.4.1.  Pre recruitment and recruitment: 
Thalassemia patients were recruited while attending the clinic for routine follow up. In 
addition we used a social network to arrange appointments with thalassemia patients to 
discuss about our research project.  
3.4.2. Sample size  
We were intending to recruit all thalassemia patients who attended their clinic during the 
study, but only twenty five participants were possible to be recruited in the study period.  
3.5. Data collection: 
3.5.1. The procedure 
All eligible patients and their parents were approached as they came in for routine 
follow-ups during the data collection period in Saqr hospital in Ras Alkhaimah. The SF 
36 Questionnaire was pretested in the former study done in 2011. Serum ferritin levels 
were collected from patient files. 
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3.5.2. Questionnaire 
The SF-36 questionnaire was chosen for its capability to evaluate both the physical and 
psychological components of quality of life. The SF-36 questionnaire assesses eight 
dimensions of health related quality of life, which relate to the physical and mental 
components of the individual’s health perception. (Figure 5) 
Specifically, the domains ‘physical functioning’(10 items) , ‘role-physical’ which means 
role limitation due to physical health problems(4 items), ‘bodily pain’(2 items), and 
‘general health’(5 items) are more related to the physical component, whereas the 
domains ‘vitality/energy’(4 items), ‘social functioning’(2 items), ‘role-emotional’ which 
means role limitations due to emotional problems (3 items), and general ‘mental 
health’(5 items) are more related to the psychological component. Possible scores for 
each domain range from 0 (corresponding to the worst possible state) to 100 
(corresponding to the best possible state). These eight domains can be grouped into 
two summary scores: the ‘physical component summary’ (PCS) evaluates the patients’ 
perception of limitations or disabilities in self-care, physical, social and role activities, the 
presence of bodily pain and fatigue. The ‘mental component summary’ (MCS) score 
evaluates the feelings of psychological distress, social and role disability because of 
emotional problems.  
The scales (Vitality, General Health, and Social Functioning) can be considered either 
physical or mental components. It is better to use the two summary measures than using 
the eight scales in statistical analysis of the SF-36 as it reduces the number of 
statistical comparison tests. In addition, the two summary measures discriminate 
between physical and mental health outcomes, cross-sectional and longitudinal studies 
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confirmed these advantages of the two summary measures. Scales of the physical 
component are most responsive to treatments that affect physical morbidity, while 
scales of the mental component respond most to therapies that act on mental health. 
The SF-36 includes only eight of 40 health concepts in the MOS (Medical 
Outcomes Study) study; in addition the SF-36 measures each concept with a short-
form scale. The content validity of the SF-36 was compared to its corresponding 
content validity of other commonly used generic health surveys (56). Comparisons 
show that the SF-36 contains eight of the most frequently used health concepts. 
However, there are several concepts included in widely-used surveys but not 
included in the SF-36. Of these concepts are: cognitive functioning, family  
functioning, health distress, sleep adequacy, sexual functioning, recreation/hobbies, 
self-esteem, eating, spirituality, communication, and symptoms/problems that are 
specific to one condition. The concept of symptoms and problems that are specific 
to a particular condition was excluded from the SF-36 because the SF-36 is a 
generic measure. 
SF-36 user’s manuals contain tables of correlations between the eight scales and 
the two summary measures and 32 measures of other general concepts (52, 53) 
and 19 specific symptoms. This correlation considers the concepts not included in 
the SF-36. 
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Items Scales Summary measures 
3a Vigorous activity  
Physical functioning 
(PF) 
Physical Health (PCS) 
3b Moderate activity  
3c Lift, carry grocery  
3d Climb several flights  
3e Climb one flight 
3f Bend, kneel 
3g Walk mile  
3h Walk several blocks  
3i Walk one block  
3j Bathe, dress  
4a Cut down time  
Role-Physical (RP) 
4b Accomplished less  
4c Limited in kind  
4d Had difficulty  
7 Pain magnitude  
Bodily Pain (BP) 
8 Pain –interfere  
1 EVGFP rating  
General Health (GH) 
11a Sock easier  
11b As healthy  
11c Health to get worse  
11d Health excellent  
9a Pep/life 
Vitality (VT) 
Mental Health (MCS) 
9e Energy  
9g Worn out  
9i Tired  
6 Social extent  
Social Functioning (SF) 
10 Social time  
5a Cut down time  
Role-Emotional (RE) 5b Accomplished less  
5c Not careful  
9b Nervous  
Mental Health (MH) 
9c Down in dumps  
9d Peaceful  
9f Blue/sad 
9h Happy  
Figure 5: SF-36 aspects (53-55) 
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It was found that SF-36 scales correlate (r = 0.40 or greater) with most of the 
excluded general health concepts in addition to the severity and frequency of many 
specific symptoms and problems. However, the correlation was not the same in 
sexual functioning that correlates weakly with SF-36 scales. So, sexual functioning 
was recommended to be included in the questionnaires that have space for 
supplementing the SF-36.  
The studies done in the United Kingdom, United States, and Sweden showed that 
the scales used in the SF-36 except General Health could explain only about two-
thirds of the variance in individual evaluations of current health status(58). 
In comparison with other published measures, SF-36 scales have been performing 
well in most tests published till now. The SF-36 was compared with 225 other 
measures(59).  
Comparing short-form versions of SF-36 with full-length versions, it was found that 
SF-36 scales perform with about 80–90% empirical validity in studies involving 
physical and mental health criteria (60). 
However, this disadvantage of the SF-36 can be balanced by the fact that some 
long-form measures have 5–10 times greater burden respondent. So, the SF-36 is 
considered a practical alternative to longer measures. In addition, eight scales and 
two summary scales cover almost all differences in physical and mental health 
status in comparisons between different group levels (56, 57, 61). Moreover, the 
SF-36 has performed equally as well as the longer non-MOS measures, such as 
the Sickness Impact Profile in detecting average group differences or changes over 
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time (61,62). Compared to longer MOS measures, using SF-36 leads to reduction 
in the statistical power of hypothesis testing. This is to be considered in planning 
clinical trials and other studies. Each scale has its own validity which is completely 
different from the validity of the other scales. This was shown in the results of factor 
analytic studies of their construct validity (Figure 6) (57,63,64). A similar trend has 
been shown for the two summary measures. 
 
 
 
Figure 6: Construct validation of the SF-36 two-component model (57). 
 
In both cross-sectional and longitudinal tests, the Mental Health, Role-Emotional 
and Social Functioning scales and the MCS summary measures were the most 
valid mental health measures. Similarly, The Physical Functioning, Role-Physical, 
and Bodily Pain scales and the PCS were found to be the most valid physical 
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health measures. Specific Criteria used in the validation of the SF-36 in known-
groups include clinical indicators of diagnosis and severity of depression, heart 
disease, and other conditions. These criteria are documented in previous reviewed 
publications and in the two user’s manuals (56,57,63-65). 
To screen for psychiatric disorders, the Mental Health scale and the MCS summary 
measure were used (57,66). For example, on using a score of 42 as a cutoff, the 
sensitivity of the MCS was 74% and its specificity was 81% in detecting patients 
diagnosed with depressive disorder (57). 
Clinical studies have shown the three scales with the most physical factor content  
(Physical Functioning, Role-Physical, and Bodily Pain) in (Figure 6) are most 
responsive to the benefits of knee replacement (68) , hip replacement (61,68), and 
heart valve surgery (69). On the other side, factor analytic studies showed that the 
three scales (Mental Health, Role-Emotional, and Social Functioning) with the most 
mental factor content  were most responsive in comparing patients before and after 
recovery from depression (64); change in the severity of depression (70); as well as 
drug treatment and interpersonal therapy for depression(71). Moreover, nearly 100 
studies showed that the SF-36 can  be used in studying the benefits of other 
treatments as well (59). 
SF-36 scales and summary measures were found to be linked to utilization of 
health care services (57), the clinical course of depression (70,72), loss of job 
within 1year, and 5-year survival (57) as shown from the results of Predictive 
validity studies. 
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Studies demonstrated the interpretation value of general and specific population 
norms for the SF-36.  General population normative data for the SF-36 has been 
collected in the United States (56,57,73) and in 12 other countries (74).This 
interpretation value has been demonstrated also for the Sickness Impact Profile 
(75) ,the MOS SF-20 (76,77) and other measures. 
At the beginning, some studies were done to validate scale scores (78). In addition, 
SF-36 scales have been increasingly accepted as valid health measures to 
document disease burden. Moreover, the advantage of a generic survey (such as 
the SF-36) in estimating disease was discussed in a group of articles about more 
than 130 diseases and conditions. Some diseases were more frequently studied as 
arthritis, back pain, depression, diabetes, and hypertension (79). Measurement was 
standardized across studies to be useful in comparing “well” and “sick” populations. 
The first IQOLA( The International Quality of Life Assessment) Project meeting was 
held in September 1991 in Paris to discuss the basic project policies and 
procedures. Permission was given for other academic researchers to use the 
IQOLA Project translations while they were in development and testing after 
signing user’s agreement before completion and testing of these translations. 
Attendants in the first IQOLA Project meeting made the translations available for 
free for all users after publication. 
In 1992-1993, more countries joined the project including Denmark and Norway. 
IQOLA research procedures were revised subsequently. Between 1993 and 1998, 
SF-36 was widely spread all over the world. 
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The IQOLA Project followed a three-stage research protocol for translating and 
testing the SF-36.The first stage was translation following a standard process 
which produced a survey form. The second stage was formal psychometric tests of 
the assumptions underlying item scoring with scale construction which lead to 
scoring algorithms. The third stage was validations and norming and the 
equivalence of interpretations across countries (80,81). 
The three stages IQOLA project produced questionnaires for data collection and 
scoring algorithms used for standardized comparisons. Lastly, the project ended 
with validation and norming studies for interpretation.  
3.5.3. Dependent variables: 
Are the scores of different components of the questionnaire; PF, RP, RE, BP, GH, VT, 
SF, MH, MCS and PCS in a scale (0–100 General Health Rating Index); these are 
numerical variables. 
3.5.4. Independent variables: 
Are categorical variables; Designations of thalassemia patients according to Quality of 
life scores, Age group, Effect of gender, splenectomy, rates of blood transfusion and 
levels of education on HRQOL. 
3.6. Data analysis 
The questionnaires were filled and collected from participants, the data were introduced 
in an excel file, and then a web site ﴾www.SF-36.org/Demos﴿ was used to change the 
scale from the scale in the SF-36 questionnaire to another scale (0–100 General Health 
Rating Index). The results from this website were introduced into an excel file again. 
36 
 
SPSS program was used for analysis of the current study findings and to compare the 
mean differences in the different components of the questionnaire; PF, RP, RE, BP, GH, 
VT, SF, MH, MCS and PCS with a previous study conducted in the same center with 
identical specifications. Independent t-tests and ANOVA were used for the inferential 
statistics. Analysis of variance (ANOVA) was followed by a posthoc test to check if the 
categories differ significantly.      
3.7. Ethical consideration and research clearance:   
3.7.1.  Ethical considerations (82-90): 
The study protocol was sent to Dubai Health Authority-UAE (the central committee) for 
judgment and approval of the Research and to Ethics Committee in RAK Medical and 
Health Sciences University (the regional committee). See appendix (1) for details.  
Our main ethical concern is taking informed consent from participants. At the beginning 
of the interview; all respondents were informed about the objectives of the study and 
were assured that all responses will remain confidential. In addition, a written consent 
was signed from the patients if they were above 18 years and from the parents, if they 
were less than 18 years old prior to the use of the questionnaire. 
 
3.7.2. Ethical clearance 
The Research and Ethics Committee clearance at RAKMHSU was obtained for a prior 
study in 2011 and ethical clearance for the current study followed the same 
specifications but for a different research team and was obtained in February 2015.  
See appendix (2) for the details.  
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3.8. Data handling: 
Questionnaires were collected and analyzed. The data were saved in a hard copy. 
Confidentiality of patients’ details was maintained and the research team only had 
access to them. 
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4. Results:  
In  this  chapter  the  results  of  data  analyses  will  be  presented.  First, 
socioeconomic and demographic characteristics of the sample, followed by personal 
opinion on health status, then quality of life scores with mean comparison of QOL 
between 2011 and 2014 studies. The main sections of this chapter are ordered in a way 
to answer the research objectives and questions. 
4.1. Socioeconomic and demographic characteristics of the sample: 
The total number of eligible patients was 25. Twenty three of them had thalassemia 
major only while two were diagnosed with thalassemia major and sickle cell anemia as 
shown in Table 1. Fourteen participants were males with a mean age of 16.7 years and 
11 were females with a mean age of 18.7 years. Half of the participants (52%) had 
received secondary education. Thalassemia was diagnosed in the first 3 years of life in 
the majority of the participants (72%) while 40% were diagnosed in their first year of life.  
Seventy six percent (76%) of the participants were from families with consanguineous 
marriage while 24% had unrelated parents. The majority of participants (76%) had 
siblings with thalassemia while only 24% had no thalassemic siblings. Twenty two 
patients (88%) have family history of thalassemia. 
Concerning the association between thalassemia and the family history of other blood 
disease, only 20% of participants had positive family history of blood disease other than 
thalassemia while the majority (80%) had negative family history. Only 6.7% had sickle 
cell anemia in addition to thalassemia major while others had thalassemia major only.   
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Majority of participants (72%) received blood transfusion at a rate of 12-24/year while 
fewer participants (20%) were on blood transfusion at a rate < 12/year. Only one patient 
received blood transfusion at a rate > 24/year and the same is found for “no blood 
transfusion”.  
All participants needed to get chelation with Desferroxamine at a rate ≤5/month. Out of 
the 25 participants, 9 (36%) were splenectomized while 16 (64%) were not 
splenectomized.  
Splenectomy was effective in reducing blood transfusion in only 12% of splenectomized   
patients while it did not reduce the rate of blood transfusion in 88% of splenectomized 
participants. The average serum ferritin of the patients was 1473.358 ng/mL. 
 
 
 
 
 
 
 
 
 
40 
 
Table 1: Socio-demographic characteristics of the participants and their quality of life 
domains 
 Males Females Total: n (%) 
Number (%) 14 (56) 11 (44) 25 (100) 
Age: (Mean± SD) 16.7 ± 8.43 18.7 ± 8.49  
Age group {n (%)}:  < 17 Years 7 (28) 5 (20) 12 (48) 
                     17 – 24 Years 5 (20) 3 (12) 8 (32) 
                      ≥ 25 Years 2 (8) 3 (12) 5 (20) 
Physical Functioning (PF)  74.3 ± 14.4 71.8 ± 16.2  
Role Physical (RP) 67.9 ± 31.7 59.1 ± 35.8  
Body Pain (BP) 64.5 ± 33.3 62.3 ± 22.3  
General Health (GH) 62.1 ± 12.7 69.9 ± 20.2  
Vitality (VT) 63.9 ± 19.03 63.2 ± 22.8  
Social Function (SF)  75.00 ± 27.95 78.6 ± 22.49  
Mental Health (MH) 64.9 ± 18.3 72.00 ± 15.39  
The physical composite scores (PCS) 6.14 ± 9.1 41.2 ± 11.13  
The mental composite scores (MCS) 46.4 ± 8.35 49.8 ± 8.8  
Hemoglobin (Hg) 8.5 ± 1.3 7.7 ± 1.78  
Education:        Not educated 1 1 2 (8) 
                Primary 5 4 9 (36) 
                      Secondary 8 5 13 (52) 
Age at which thalassemia was diagnosed 
 ≤ 1 year 6 4 10 (40) 
 1 – 3 years 4 4 8 (32) 
 3-5  years 2 3 5 (20) 
               ˃5 2  2 (8) 
Parents consanguinity:            Yes / No 9 / 5 10 / 1 19 (76) / 6 (24) 
Siblings status of thalassemia:Yes / No 13 / 1 6 / 5 19 (76) / 6 (24) 
Family history of thalassemia: Yes / No 14 / 0 8 / 3 22 (88) / 3 (12) 
Types of thalassemia    
       Thalassemia major 13 10 23 (92) 
       Thalassemia major + Sickle cell 
anemia 
1 1 2 )8( 
Rate of blood transfusion/ year    
              < 12 3 2 5 (20) 
               12-24 11 7 18 (76) 
Times of chelation/ month:      
               ≤5 
 
25 (100) 
Splenectomy:                              Yes / No 4 / 10 5 / 6 9 (36) / 16 (64) 
Effectiveness of splenectomy in reducing blood transfusion: 
                Yes / No 2 / 12 1 / 10 3 (12) / 22 (88) 
 One male and one female did not go to school at all, whereas one female has higher education.  
 Only one girl has not been given blood transfusion yearly, while one female was given more than 24 
times. 
 Other blood diseases can be inherited in families with Thalassemia as sickle cell anemia,G6PD 
deficiency anemia and hemophilia was found in 5 (20%) only. 
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4.2. Personal opinion on health status  
4.2.1.  Frequency of personal opinion on health in general: 
Twenty eight percent (28%) of the patients thought that their general health was good, 
32% thought it was very good and a further 16% said it was excellent (Table 2).  
4.2.2. Proportion of patients in each category of personal opinion on health 
status compared to one year ago: 
Compared to one year ago, 20% said that their health now was similar to one year ago 
while 56% thought it was much better than one year ago(Table 3). 
 
Table 2: Frequency of personal opinion on health in general 
Personal opinion n (%) 
Poor  1 (4) 
Fair 5 (20) 
Good 7 (28) 
Very good 8 (32) 
Excellent 4 (16) 
 
Table 3: Proportion of patients in each category of personal opinion on health status 
compared to one year ago 
Personal Opinion 
n (%) 
Somewhat worse now than one year ago 1 (4) 
About the same 5 (20) 
Somewhat better now than one year ago 5 (20) 
Much better now than one year ago 14 (56) 
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4.3. Quality of life scores 
Scores on quality of life ranging from 0 to 100 were obtained and categorized on an 
ordinal scale from weak to excellent. For example, a score between 80 and 100 
indicates excellent of quality of life for each of the 8 indices. The distribution of the 
proportion of patients with an excellent score were as follows; 7 patients (28%) for 
physical functioning, 8 (32%) for Role-physical, 7 (28%) for bodily pains, 5 (20%) for 
general health, 5 (20%) for vitality, 7 (28%) for social functioning, 13 (52%) for role-
emotional, and 3 (12%) for mental health (Table 4). 
4.3.1. Designations of thalassemia patients according to Quality of life scores 
Table 4: Designations of thalassemia patients according to Quality of life scores 
(Current study 2014) 
Score PF RP BP GH V SF RE MH 
Excellent 7(28%) 8(32%) 7(28%) 5(20%) 5(20%) 7(28%) 13(52%) 3(12%) 
Very good 13(52%) 6(24%) 7(28%) 13(52%) 9(36%) 4(16%) - 14(56%) 
Good 5(20%) 5( 20%) 6(24%) 4(16%) 8(32%) 4(16%) - 6(24%) 
Bad - 4(16%) 3(12%) 3(12%) 3(12%) 1(4%) - 2(8%) 
Weak - 2(8%) 2(8%) - - - 4(16%) - 
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4.3.2. Mean comparison of quality of life between 2011 and 2014 studies: 
A comparison of quality of life between patients in the former study of 2011 and the 
current 2014 study showed significant difference in all the domains except physical 
functioning and vitality, with the highest mean difference of -54.0 observed in the role-
physical (Table 5). The differences were significant for Role-Physical, Body Pain, 
General Health, Social functioning, Role-emotional, Mental Health and Mental 
composite summary (p value˂0.05).  In addition, there was a significant difference in 
mental composite summary while the physical composite summary showed insignificant 
difference (Table 5). 
Table 5: Mean and SD of SF-36 domain and summary scores among thalassemia 
patients in former study (2011) compared with current study (2014) 
 
Former study 
2011 (Mean ± SD) 
Current study 
2014 (Mean ± SD) 
Difference P-value 
 Physical Functioning 74.2 ± 13.28 73.20 ± 14.92 1,000 0,80 
   Role-Physical 10 ± 28 64.00 ± 33.14 -54,000 < 0.01 
 Body Pain 45.6 ± 16 63.52 ± 28.43 -17,920 0.01 
     General Health 46.92 ± 24.37 65.56 ± 16.55 -18,640 < 0.01 
  Vitality 53.2 ± 20.35 63.60 ± 20.34 -10,400 0,08 
   Social functioning 53 ± 20.19 76.56 ± 24.95 -23,56250 0,002 
 Role-emotional 34.66 ± 46.6 76.47 ± 43.72 -41,80659 0,01 
 Mental Health 48.32 ± 16.7 68.00 ± 17.13 -19,68000 < 0.01 
 Physical composite 
summary 
39.49 ± 5.9 43.97 ± 10.15 -4,21800 0,08 
  Mental composite 
summary 
37.22 ± 10.5 47.90 ± 8.56 -10,68400 < 0.01 
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4.3.3. Age group differences in the differnt apsects of the questionare. 
Physical Functioning, Role-Physical, Vitality,  Role-emotional ,Physical composite 
summary and Mental composite summary mean scores were highest in the age group < 
17 years compared to the other age groups as shown in Table 6. However, Body Pain, 
General Health and Mental Health mean scores were highest in the age group ≥ 25 
years compared with the other age groups. Social functioning was highest in age group   
≥ 25 but equal in the age groups < 17 years and 17 – 24 years (Table-6). 
 
Table 6: Age group differences in the differnt apsects of the questionare. 
 
< 17 Years 
Mean ± SD 
17 – 24 Years 
Mean ± SD 
≥ 25 Years 
Mean ± SD 
 Physical Functioning 77.92 ± 14.22 65.63 ± 14.75 74,00 ±14.75 
 Role-Physical 66.67 ± 26.83 59.38 ± 35.20 65.00 ± 48.73 
  Body Pain 67.75 ± 28.16 52.50 ± 29.74 71.00 ± 27.50 
 General Health 65.33 ± 17.42 63.38 ± 18.97 69.60 ± 12.20 
  Vitality 70.83 ± 19.29 51.25 ± 18.66 66.00 ±19.49 
 Social functioning 75.00 ± 29.88 75.00 ± 20.41 81.25 ± 23.94 
 Role-emotional 87.50 ± 35.36 60.00 ± 54.77 75.00 ± 50.00 
 Mental Health 70.00 ± 16.40 61.50 ± 18.88 73.60 ± 16.15 
 Physical composite 
summary 43.76 ± 11.23 42.93 ± 9.14 46.14 ± 10.79 
 Mental composite 
summary 49.12 ± 9.92 44.59 ± 6.82 50.00 ± 7.37 
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4.3.4. Effect of gender, splenectomy, blood transfusion and education on 
HRQOL 
No statistically significant differences were found between males and females in 
HRQOL as shown in Table 7.  
Table 7: Comparison between males and females in HRQOL score using the 
independent T-test 
 
Test variable 
Males 
Mean ± SD 
Females 
Mean ± SD 
Mean 
difference 
P-value 
 Physical Functioning 74.3 ± 14.4 71.8 ± 16.2 2.5 0.69 
 Role-Physical 67.9 ± 31.9 59.1 ± 35.8 8.8 0.52 
 Body Pain 64.5 ± 33.3 62.3 ± 22.3 2.2 0.85 
 General Health 62.1 ± 12.7 69.9 ± 20.2 -7.7 0.25 
 Vitality 63.9 ± 19.0 63.2 ± 22.8 0.75 0.93 
 Social functioning 75 ± 28.0 78.6 ± 22.5 -3.6 0.79 
 Role-emotional 66.7 ± 50.0 87.5 ± 35.4 -20.8 0.34 
 Mental Health 64.9 ± 18.3 72.0 ± 15.4 -7.1 0.31 
 Physical composite 
summary 
46.1 ± 9.1 41.2 ± 11.1 4.9 0.23 
 Mental composite 
summary 
46.4 ± 8.4 49.8 ± 8.8 -3.4 0.33 
 
HRQOL scores were also not significantly different between patients with splenectomy 
and those without (table 8). 
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Table 8: Comparison between patients with splenectomy and those without in HRQOL 
score using the independent T-test 
 
Test variable 
Splenectomy 
Mean ± SD 
No splenectomy 
Mean ± SD 
Mean 
difference 
P-value 
 Physical 
Functioning 
69.4 ± 17.8 75.3 ± 13.2 5.9 0.36 
 Role-Physical 55.6 ± 41.0 68.8 ± 28.1 13.2 0.35 
 Body Pain 55.7 ± 32.2 67.9 ± 26.2 12.3 0.31 
 General Health 71.0 ± 17.8 62.5 ± 15.5 -8.5 0.23 
 Vitality 59.4 ± 24.4 65.9 ± 18.1 6.5 0.46 
 Social functioning 80.0 ± 20.9 75.5 ± 27.4 -5.0 0.72 
 Role-emotional 66.7 ± 51.6 81.8 ± 40.5 15.2 0.51 
 Mental Health 69.3 ± 21.9 67.3 ± 14.5 -2.1 0.78 
 Physical 
composite 
summary 
43.2 ± 10.5 44.4 ± 10.3 1.1 0.80 
MCS Mental 
composite 
summary 
48.7 ± 9.0 47.5 ± 8.6 -1.2 0.75 
 
Patients with less blood transfusion (<12/year) had better quality of life in 7 out of the 
eight SF-36 domains in comparison with patients with more blood transfusion. However, 
the only difference that was significant statistically is general health (table 9). 
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Table 9: ANOVA (KW test) table showing mean differences between different rates of 
blood transfusion on HRQOL 
 
Test variable 
Rate of transfusion P-value 
0** 1 2 3** 
Mean ± 
SD 
Mean ± SD Mean ± SD Mean ± SD 
 Physical 
Functioning 
90.0 63 ± 17.5 76.1 ± 12.9 55.0 0.12 
 Role-Physical 75.0 65.0 ± 33.5 61.1 ± 34.5 100.0 0.72 
 Body Pain 100.0 49.4 ± 32.7 66.1 ± 27.2 52.0 0.38 
 General Health 90.0 49.8 ± 13.8 68.8 ± 14.9 62.0 0.05 
 Vitality 80.0 53.0 ± 23.6 66.4 ± 19.6 50.0 0.45 
 Social functioning 100.0 75.0 ± 35.4 75.0 ± 22.4 - 0.66 
 Role-emotional 100.0 100.0 ± 0.0 66.7 ± 49.2 100.0 0.60 
 Mental Health 92.0 64.0 ± 14.1 67.1 ± 17.9 80.0 0.45 
 Physical 
composite 
summary 
52.9 39.4 ± 11.1 44.9 ± 10.2 40.0 0.58 
 Mental composite 
summary 
59.7 47.5 ± 8.0 47.1 ± 8.8 53.4 0.50 
**Only one patient in this group 
As shown in Table 10, patients with higher educational level (secondary school or more) 
had better quality of life in comparison with those who had lower educational level. This 
occurs in all the domains except in vitality, where the quality of life was higher in primary 
school holder than the higher degrees. However, there was insignificant difference 
between the quality of life and educational level in any of the domain scores or the 
summary scores (all p values are ˃0.05).  
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Table 10: ANOVA table showing mean differences between different levels of education 
on HRQOL 
Test variable Level of Education P-value 
Not in school Primary Secondary More** 
Mean ± SD Mean ± SD Mean ± SD Mean ± SD 
Physical 
Functioning 
72.5±10.6 73.9±17.3 71.9 ± 14.9 85.0 0.88 
Role-Physical 75.0±35.4 55.6±34.9 65.4 ± 33.1 100.0 0.60 
Body Pain 51.5±0.7 65.3±33.8 64.2 ± 28.7 62.0 0.95 
General Health 57.5±10.6 67.7±17.2 63.5 ± 16.5 90.0 0.41 
Vitality 67.5±3.5 71.7±21.7 56.2 ± 19.5 80.0 0.29 
Social functioning 62.5±53.0 85.0±22.4 75.0 ± 23.1 75.0 0.78 
Role-emotional 100.0 75.0±46.3 71.4 ± 48.8 100.0 0.90 
Mental Health 78.0±2.8 60.9±23.6 71.1 ± 12.1 72.0 0.46 
Physical composite 
summary 
41.7±2.3 42.5±12.5 44.7 ± 9.6 52.0 0.83 
Mental composite 
summary 
51.9±10.0 46.8±12.0 47.7 ± 6.1 52.0 0.85 
**Only one patient in this group 
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5. Discussion: 
The aim of this study was to study the impact of the diseases on the physical and 
psychological activity of thalassemia patients and to study the different clinical and 
therapeutic factors such as rate of blood transfusion and chelation therapy on physical 
and psychological well-being of those patients. 
 
5.1. Results of QOL: 
The highest domain score in the current study was in physical functioning (73.20 ± 
14.92) which was nearly the same in the former study (74.2± 13.28). Dahlui et al, (2009) 
(2012) and Safizadeh et al, explained the high physical functioning score by saying that 
these patients had low expectations of physical performance because they have been 
living with the disease for long time without the burden of work (45,91). 
The lowest domain scores in our current study were in Role-Physical (64.00 ± 33.14), 
Body Pain (63.52 ± 28.43), Vitality (63.60 ± 20.34) and General Health (65.56 ± 16.55). 
In the former study, the lowest domain score was in Role-Physical (10 ± 28). Safizadeh 
et al (2012) found lowest scores in the general health and role-physical domains (45). 
In the current study, Physical Functioning, Role-Physical, Vitality, Role- emotional, 
Physical composite summary and Mental composite summary were the best in age 
group < 17 years followed by age group   ≥ 25 years followed by age group 17 – 24 
years. However, Body Pain, General Health and Mental Health were highest in age  
group   ≥ 25 years followed by < 17 years  followed by 17 – 24 years. Social functioning 
was highest in age group   ≥ 25 while it was equal in groups < 17 years and 17 – 24 
years. However, in the former study, the quality of life was better in the age group (17-
24 years) compared to elder and younger age groups. 
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The female participants had higher domain scores in GH, SF, MH and RE while RP 
score was higher in males than in females. However, the male participants had slightly 
higher domain scores in PF, BP and VT.  
The differences in the domains were insignificant as shown by p values ˃0.05. 
Safizadeh et al (2012) found that female participants had a higher score in all domains 
except for BP, when compared to the male participants(45) . Males have many stresses 
and challenges in their life as sponsoring their families and job stresses. 
Patients with higher educational level (secondary school or more) in this study had 
better quality of life in comparison with those who had lower educational level. This 
occurs in all the domains except in vitality, where the quality of life was higher in primary 
school holder than the higher degrees. However, there was insignificant difference 
between the quality of life and educational level in any of the domain scores or the 
summary scores (all p values are ˃0.05). The Ministry Of Health in the UAE has been 
providing massive health education campaigns for thalassemic patients with different 
education levels. Health education helps to increase awareness about the disease 
which improves the quality of life. In addition, health educators explain to the patients 
how thalassemia is inherited through the family which decreases the occurrence of new 
cases (92). One of the main tests included in the premarital examination in the UAE is a 
test for thalassemia. This examination is mandatory before marriage; premarital 
examination includes counseling the married couple about thalassemia. 
Furthermore, patients with less blood transfusion (<12/year) had better quality of life in 7 
out of the eight SF-36 domains in comparison with patients with more blood transfusion. 
However, the only difference that was significant statistically is general health. There 
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was only one patient receiving blood transfusion ≥24 times/year and one patient without 
blood transfusion that was not enough to study the effect of the rate of blood transfusion 
on the health related quality of life. It was found that patients who need more transfusion 
are those who had more severe disease with more complications in addition to the 
burden and complications of blood transfusion itself (93); this can explain the difference 
in the quality of life with different rates of blood transfusions. 
In the previous study on the same population, more than (50%) were receiving blood 
transfusion ≥24 times/year while fewer patients (24%) were receiving blood transfusion 
<12 times per year while in our study, the Majority of participants (76%) received blood 
transfusion at a rate of 12-24/year while fewer participants (20%) were on blood 
transfusion at a rate < 12/year. Only a small proportion of the participants (4%) received 
blood transfusion at a rate > 24/year while a similar proportion (4%) did not receive 
blood transfusion. 
Oral iron chelation became available to all patients who became more compliant with 
regular administration of their iron chelation; this helped to improve HRQOL of our 
patients more than those of the previous study.  
The average serum ferritin of the patients was 1473.358 ng/mL, which is a little bit 
higher than the average serum ferritin level in the first study. 
 This can be explained by knowing that serum ferritin is not the most reliable test as it is 
an acute phase protein that does not exactly reflect the status of hemochromatosis. A 
more reliable test is MRI showing iron deposition in different body organs (94) which 
was not available and is not done routinely for those patients. Besides MRI cannot be 
used for children under 10 years because they cannot react to MRI machine. The other 
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point to explain the serum ferritin difference in spite of better result with regards to QOL 
aspects is that it was difficult to recruit exactly the same patients in the study done in 
2011, yet it was possible to recruit the same number; 25 patients. This was because 
one of the patients in the first study died and other participant left UAE to his mother 
country, Jordan. 
If we compare these results to the results of the study done in the same center three 
years earlier, we will find that in the previous study (53%) were in general, in a good 
health. Compared to one year ago, in the former study, (48%) said that their health now 
is the same as compared to previous year, while (36%) said it is now much better than 
one year ago which may reflect the improved patients perception about their health with 
the progress of treatment policy followed in Saqr Hospital.  
 
5.2. Strengths and Limitation of methodology: 
The  following  sections  will  provide  a  discussion of the methodological  weaknesses  
and  strengths  in  the  research  done with an account on  validity  and  reliability   of  
the  research.   
5.2.1. Strengths of SF-36: 
 It can measure the health status in different groups and different diseases and even 
give us the ability to compare between them. In addition, it can be used for follow up the 
patients during their chronic diseases and see the impact of the disease, its 
complications and management on the quality of life. Moreover, the SF-36 takes short 
time to administer with good to excellent reliability and validity and it can be used to 
produce more detailed questionnaires for more precise and more specific measures. It 
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can be said that this questionnaire evaluates both the physical and psychological 
components of quality of life of our patients. Lastly, the translation of the questionnaire 
and the interviews were carried by researchers talking the same language of the 
patients; Arabic. This helped clearly to reduce the misunderstanding or ambiguity of 
responses.  
5.2.2. Limitations of SF-36: 
First of all, without a control group it is not possible to know whether changes in self-
rated functioning and well-being would have occurred in individuals without the same 
condition. In addition, the SF-36 is a generic measure and may not adequately capture 
all areas of functioning and well-being that are relevant to people with thalassemia; 
optimally, a disease-specific instrument should be used alongside it. Concerning 
analysis, the correlational design of the analyses leaves the potential for other 
unmeasured factors to contribute to, or confound, the observed relationships. Moreover, 
because the measurement of quality of life is new and without the presence of specific 
guidelines, there are some difficulties in the interpretation of the results. Finally, SF-36 
reflects the patients’ perception to their health, which might not reflect the real clinical 
situation. In our study, the small sample size was not enough to give in depth as if it was 
a large sample size. 
5.2.3. Reliability 
Reliability and validity are two concepts that are important for defining and measuring 
bias and distortion. Reliability is the degree to which a measurement technique can be 
depended upon to secure consistent results upon repeated application making it one 
of the most important elements of test quality. The minimum standard of reliability 
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which is recommended for measures used in group comparisons is 0.70(95).  In 
previous published studies, reliability for the same test frequently exceeded 0.80 in most 
of them (96).  
To reduce systematic variations all interviews were conducted by the same researcher.  
We tried to reduce Observer variations by asking the same questions to all respondents, 
and by using a standard questionnaire SF-36. However, questions often needed to be 
rephrased or central concepts explained, so that the respondent understood the 
meaning.  
5.2.4. Validity 
Validity refers to the degree in which our test or other measuring device is truly 
measuring what we intended it to measure or, in other terms, the accuracy of an 
assessment. It is the most important measure of the quality of a test as it is concerned 
with the meaning and interpretations of scores. The SF-36 is used in different 
applications, so its validity was proven.  
The two aspects of validity; internal and external validity, were considered here.  
The internal validity which shows how accurately the data and the conclusions drawn 
from the data represent what really happened was assured by translating the SF-36 
questionnaire into Arabic to fit the patients who speak Arabic. In addition the 
interviewer, as mentioned before, speaks the same language. Moreover, the same 
questionnaire with the same context was used for the study group in 2011. However, 
there was unavoidable bias in the data gathering represented as follows. First, the 
selection bias; as It was intended to recruit all attendants to thalassemia clinic (60 
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patients registered), but we could recruit only 25 patients, this cannot exclude selection 
bias. Second, the information bias where selection was not randomized and participant 
individuals differ in their ability to express their feelings, this might cause information 
bias. Confounding bias was inevitable also as the answers of the participants might be 
affected by other confounding factors as psychosocial status and mood condition, this 
could cause confounding bias. 
The external validity shows how accurately the data and the conclusions from the 
data can be generalized to the larger population. Surely, the work done in our study 
can be repeated in thalassemic patients throughout UAE and abroad as explained in 
the following account.  
 Thalassemia patients are followed up in different thalassemia centers all over the UAE. 
In addition the ministry of health (MOH) in the UAE provides patients with oral iron 
chelation therapy for all patients in all thalassemia centers following the international 
standards. Moreover, the Ministry Of Health implements continuous health education 
programs and premarital examination program all over the UAE. So, our study can be 
replicated in different places in the UAE. The SF-36 is used in different applications, so 
various types of validity are relevant as content, concurrent, construct, criterion, and 
predictive validity. (97) 
  However, the small sample size makes it difficult to represent the total population of 
the United Arab Emirates. 
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6. Conclusion 
Quality of life in thalassemic patients was higher in the second study done in 2014 than 
in the first study done in 2011. The domains mostly affected were the role-physical and 
role-emotional. Thalassemia disease limits the physical and emotional ability of the 
patients, this change can be explained by several factors, first of all the availability of 
the oral iron chelating medicine, so all patients became more compliant with their iron 
chelating therapy. In addition, health education programs increased the awareness 
about thalassemia among patients and their families and the patients became more 
involved in social networks.  
7. Recommendations and implications 
This  study  has  implication  for  both  practice  and  future  areas  of  research. We 
recommend that all patients with thalassemia should regularly undergo assessment of 
the quality of life. There is a knowledge gap in this area of research which requires 
repeated and continuous research to explore more about HRQOL in thalassemia 
patients, thus we can plan intervention programs that focus on the affected domains. In 
addition, intervention programs should include support of the patients and their families 
especially the psychological support to avoid mental disorders. (98-100)  
Lastly, we recommend repeating our study every other year and on a wider scale 
recruiting more thalassemia patients. In thalassemia center in Dubai 
(http://www.thalassemia-dubai.com/default.aspx), there are about 850 thalassemia 
patients registered for treatment and follow up. This is a good place to recruit much 
more patients.  
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Appendix 2:  Consent regulations in the Health Authorities in the UAE and the 
researchers comments on its clauses. 
 
CONSENT FORM ABOVE 18 YEARS OF AGE:  
Concerning the process of obtaining informed consent the CIOMS guidelines emphasize that the 
sponsors and the investigators have the obligation to:  
- refrain from unjustified deception, undue influence, or intimidation.  
- seek consent only after ascertaining that the prospective subject has adequate understanding of 
the relevant facts and of the consequences of participation and has had sufficient opportunity to 
consider whether to participate;  
 - As a general rule, obtain from each prospective subject a signed form as evidence of informed 
consent. 
 – Investigators should justify any exceptions to this general rule and obtain the approval of the 
ethical review committee. 
The normal procedure today is that consent is sought after the trial person has been given an 
oral orientation and received written information about the project.  
ICH GCP E6; section 4.8-4.8.14   
4.8.6 The language used in the oral and written information about the trial, including the written 
informed consent form, should be as non-technical as practical and should be understandable to 
the subject or the subject's legally acceptable representative and the impartial witness, where 
applicable. 
The standard Forward-Backward procedure was applied to translate the SF-36 questionnaire 
from English to Arabic by a bilingual individual with some cultural adaptation, this is to make it 
easy and understandable for participants. 
4.8.10 Both the informed consent discussion and the written informed consent form and any 
other written information to be provided to subjects should include explanations of the 
following:  
a) That the trial involves research.  
b) The purpose of the trial.  
In the general information part of the consent form, we explained everything about the study and 
gave enough time and chance for any question to be answered, in addition, we explain the 
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purpose of the study. 
Part of the consent form states: 
As part of the research we are asking thalassemic patients to fill in questionnaires so that we can 
learn more about the physical and mental impact of thalassemia and its management on the 
quality of life in more detail.  
If you agree, you will be asked to complete a questionnaire; the questionnaire will be explained 
to you by the researcher who will answer any questions you have about how to fill it in.  
The questionnaire has been carefully developed; it contains questions about a range of physical 
symptoms and activities, your emotional wellbeing and other aspects of your everyday life. There 
are no 'right' or 'wrong' answers – we simply want to find out your personal perception of your 
physical and mental activities.  
h) The reasonably expected benefits. When there is no intended clinical benefit to the subject, the 
subject should be made aware of this.  
We explained to participants that there is limited research examining the factors associated with 
HRQOL in children and adolescents with thalassemia, information from this study will help us 
for better understanding of these factors, and as a result to develop more suitable clinical, 
counseling, and social support programs to enhance treatment outcomes, especially in terms of 
HRQOL of these patients, in addition, at-risk groups of children and adolescents could be 
identified as candidates for proactive care assistance. Given the insufficient research in this area, 
this study aims to focus on patient perspective.  
k) The anticipated prorated payment, if any, to the subject for participating in the trial.  
It is clear in the consent form that there is no money incentive for participating in the study 
as shown in the next statement in the consent form: 
 also understand that I will not receive money for participation in this study.  
l) The anticipated expenses, if any, to the subject for participating in the trial.  
The consent form states: 
 I understand that I will not be charged additional expenses for my participation in this study.   
M) That the subject's participation in the trial is voluntary and that the subject may refuse to 
participate or withdraw from the trial, at any time, without penalty or loss of benefits to which 
the subject is otherwise entitled.  
Part of the consent form states: 
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 I understand that I am free to withdraw my consent to participate in this study, i may 
withdraw consent at any time and this decision will not adversely affect my care. 
N) That the monitor(s), the auditor(s), the IRB/IEC, and the regulatory authority (ies) will be 
granted direct access to the subject's original medical records for verification of clinical trial 
procedures and/or data, without violating the confidentiality of the subject, to the extent 
permitted by the applicable laws and regulations and that, by signing a written informed consent 
form, the subject or the subject's legally acceptable representative is authorizing such access.  
O) That records identifying the subject will be kept confidential and, to the extent permitted by 
the applicable laws and/or regulations, will not be made publicly available. If the results of the 
trial are published, the subject’s identity will remain confidential. 
The names of participants will be omitted from the questionnaire papers. 
 This is shown in our consent form which states: 
 All data obtained from this research will remain confidential and will only be used for 
research purposes, the confidentiality of this document and all records from this research will be 
protected to the extent provided by law. Neither my name nor any other family member's name 
will be used in any report.  
UNDER 18 YEARS OF AGE : 
Written consent was required from patients if they were above 18 years and from the patient’s 
parents, if they were less than 18 years old prior to the use of the questionnaire.  
ICH GCP E6; section 4.8-4.8.14  
4.8.7 Before informed consent may be obtained, the investigator, or a person designated by the 
investigator, should provide the subject or the subject's legally acceptable representative ample 
time and opportunity to inquire about details of the trial and to decide whether or not to 
participate in the trial. All questions about the trial should be answered to the satisfaction of the 
subject or the subject's legally acceptable representative. 
This was done as an introductory general information part of the informed consent form.   
4.8.8 Prior to a subject’s participation in the trial, the written informed consent form should be 
signed and personally dated by the subject or by the subject's legally acceptable representative, 
and by the person who conducted the informed consent discussion.  
Part of our informed consent form says: 
 My signature below indicates that I have read all the above information, received answers 
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concerning areas I do not understand, and I am willingly giving my consent for my child to 
participate in this program.  
 On signing this form, I will receive a copy. 
In the information part of our questionnaire, we explain in details about the questions and will 
give chance to any question or explanation from the participant.    
4.8.14 Non-therapeutic trials may be conducted in subjects with consent of a legally acceptable 
representative provided the following conditions are fulfilled:  
a) The objectives of the trial cannot be met by means of a trial in subjects who can give informed 
consent personally. 
b) The foreseeable risks to the subjects are low.  
In our study there is foreseeable risk. 
c) The negative impact on the subject’s well-being is minimized and low. 
There is minimal effect on our participants.  
 d) The trial is not prohibited by law.  
It is a questionnaire about life style of thalassemia patients which is not prohibited by law in 
UAE. 
e) The approval/favourable opinion of the IRB/IEC is expressly sought on the inclusion of such 
subjects, and the written approval/ favourable opinion covers this aspect.  
In our study 4.8.7,4.8.8, 4.8.14 are fulfilled as shown in the consent form for participants under 
18years age. 
 The DoH states that  
"For a research subject who is legally incompetent, physically or mentally incapable of giving 
consent or is a legally incompetent minor, the investigator must obtain informed consent from 
the legally authorized representative in accordance with applicable law. These groups should 
not be included in research unless the research is necessary to promote the health of the 
population represented and this research cannot instead be performed on legally competent 
persons."  
Thalassemia is a hereditary genetic disease starting from child birth till the end of life. So we 
cannot ignore the group of participants under 18 years as they are one of the two categories of 
participants. 
"When a subject deemed legally incompetent, such as a minor child, is able to give assent to 
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decisions about participation in research, the investigator must obtain that assent in addition to 
the consent of the legally authorized representative."  
In our questionnaire, we took assent of participants below 18 years age.  
Confidentiality: 
When data are used for research purposes, the participant's names are omitted to keep privacy.  
The Helsinki declaration paragraph 21 states that researchers have to protect the integrity of the 
trial person: Every precaution should be taken to respect the privacy of the subject, the 
confidentiality of the patient’s information and to minimize the impact of the study on the 
subject’s physical and mental integrity and on the personality of the subject.  
Confidential personal information should be treated in a way to avoid breaking confidentiality. 
The 1991 international guidelines for ethical review of epidemiological studies states that 
research may involve collecting and storing data relating to individuals and groups, and such 
data, if disclosed to third parties, may cause harm or distress. Consequently, investigators 
should make arrangements for protecting the confidentiality of such data by, for example, 
omitting information that might lead to the identification of individual subjects, or limiting 
access to the data, anonymizing data or by other means.  
A part of the informed consent form says: 
 All data obtained from this research will remain confidential and will only be used for 
research purposes. The confidentiality of this document and all records from this research will 
be protected to the extent provided by law. Neither my child's name nor any other family 
member's name will be used in any report.  
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Appendix 3: Comprehensive results of the study 
Variable Males   Females   Total 
(%) 
N 14 11 25 
Education    
 Not at school 1 1 2 
 Primary 5 4 9 
 Secondary 8 5 13 
 More - 1 1 
Age at which thalassemia was diagnosed    
 < 1 year 6 4 01 
 1 – 3 years 4 4 8 
 4 – 5 years 2 3 5 
 > 5 years 2  2 
Consanguineous marriage of parents    
 No 5 0 6 
 Yes 9 01 09 
Siblings status of thalassemia    
 No 0 5 6 
 Yes 03 6 09 
Family history of thalassemia    
               No  3 3 
               Yes 14 8 22 
Family history of any other blood disease 
Like(sickle cell anemia,G6PD deficiency anemia, hemophilia) 
   
               No 11 9 20 
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              Yes 3 2 5 
Rate of blood transfusion/year    
              0  1 1 
               ˂12 3 2 5 
               12-24 11 7 18 
               ˃24  1 1 
Splenectomy(removal of the spleen)    
               No 10 6 16 
               Yes 4 5 9 
Effectiveness of splenectomy in reducing blood transfusion    
                No 12 10 22 
                Yes 2 1 3 
In general, would you say your health is    
                Poor 1  1 
                Fair 3 2 5 
                Good 3 4 7 
                Very good 5 3 8 
                Excellent 2 2 4 
Compared to one year ago, how would you rate your  health in 
general now 
   
               Somewhat worse now than one year ago 1  1 
               About the same 3 2 5 
              Somewhat better now than one year ago 2 3 5 
               Much better now than one year ago 8 6 14 
Vigorous activities, such as running, lifting heavy objects, 
participating in strenuous sports? 
   
            No, Not Limited At All               2 2 4 
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               Yes, Limited A Little 10 6 16 
               Yes, Limited A Lot 2 3 5 
Moderate activities, such as moving a table, pushing a vacuum 
cleaner, bowling, or playing golf? 
   
            No, Not Limited At All               9 6 15 
               Yes, Limited A Little 5 4 9 
               Yes, Limited A Lot  1 1 
Lifting or carrying groceries?    
            No, Not Limited At All               6 7 13 
               Yes, Limited A Little 7 4 11 
               Yes, Limited A Lot 1  1 
Climbing several flights of stairs?    
            No, Not Limited At All               3 4 7 
               Yes, Limited A Little 7 4 11 
               Yes, Limited A Lot 4 3 7 
Climbing one flight of stairs?    
            No, Not Limited At All               12 10 22 
               Yes, Limited A Little 2 1 3 
Bending, kneeing or stooping?    
            No, Not Limited At All               9 5 14 
               Yes, Limited A Little 3 5 8 
               Yes, Limited A Lot 2 1 3 
Walking more than a mile?    
            No, Not Limited At All               4 2 6 
               Yes, Limited A Little 6 4 10 
               Yes, Limited A Lot 4 5 9 
Walking several blocks?    
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            No, Not Limited At All               9 6 15 
               Yes, Limited A Little 4 4 8 
               Yes, Limited A Lot 1 1 2 
Walking one block?    
            No, Not Limited At All               13 10 23 
               Yes, Limited A Little 1 1 2 
Bathing or dressing yourself?    
            No, Not Limited At All               14 10 24 
               Yes, Limited A Little  1 1 
Cut down on the amount of time you spent on work/school or other 
activities? 
   
                No 9 7 16 
                Yes 5 4 9 
Accomplished less than you would like?    
                No 9 6 15 
                Yes 5 5 10 
Were limited in the kind of work or other activities?    
                No 00 9 21 
                Yes 3 2 5 
Had difficulty performing the work, school or other activities (for 
example it took  
extra effort)? 
   
                No 9 5 04 
                Yes 5 6 00 
Cut down on the amount of time you spent on work/school or other 
activities? 
   
                No 9 9 08 
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                Yes 5 2 7 
Accomplished less than you would like?    
                No 01 8 08 
                Yes 4 3 7 
Didn’t do work or other activities as carefully as usual?    
                No 9 8  
                Yes 5 3  
During the past 4 weeks, to what extent has your physical health or 
emotional  
problems interfered with your normal social activities with family, 
friends, neighbors,  
or groups? 
   
              Not at all 5 3 8 
              Slightly 3 0 4 
                    Moderately 6 5 00 
                    Extremely  2 2 
How much bodily pain have you had during the past 4 weeks?    
                    None 6 2 8 
                    Mild 3 6 9 
                    Moderate 1 1 2 
                    Severe 3 2 5 
                     Very severe 1  1 
During the past 4 weeks, how much did pain interfere with your 
normal work (including  
both work outside the home and housework)? 
   
                   Not at all 6 1 7 
                   Slightly 3 3 6 
                   Moderately 3 6 9 
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                   Quite a bit 1  1 
                   Extremely 1 1 2 
Did you feel full of pep?    
                   Most of the time  2 2 
                   A good bit of the time 4 3 7 
                   Some of the time 2 1 3 
                   A little of the time 6 3 9 
                   None of the time 2 2 4 
Have you been a very nervous person?    
                 All of the time 1 1 2 
                   Most of the time 6 3 9 
                   A good bit of the time 3 5 8 
                   Some of the time  2 2 
                   A little of the time 3  3 
                   None of the time 1  1 
Have you felt so down in the dumps that nothing could cheer you 
up? 
   
                 All of the time 3 4 7 
                   Most of the time 3 4 7 
                   A good bit of the time 4 1 5 
                   A little of the time 3 1 4 
                   None of the time 1 1 2 
Have you felt calm and peaceful?    
                 All of the time  1 1 
                   Most of the time 1  1 
                   A good bit of the time 3 1 4 
                   Some of the time 3 3 6 
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                   A little of the time 4 3 7 
                   None of the time 3 3 6 
Did you have a lot of energy?    
                 All of the time 1  1 
                   Most of the time 2 2 4 
                   A good bit of the time 2 5 7 
                   Some of the time  1 1 
                   A little of the time 6 1 7 
                   None of the time 3 2 5 
Have you felt downhearted and blue?    
                 All of the time 4 4 8 
                   Most of the time 7 4 11 
                   A good bit of the time 2 2 4 
                   Some of the time  1 1 
                   None of the time 1  1 
Do you feel worn out?    
                 All of the time 1 3 4 
                   Most of the time 5 4 9 
                   A good bit of the time 4 3 7 
                   Some of the time 1 1 2 
                   A little of the time 1  1 
                   None of the time 2  2 
Have you been a happy person    
                 All of the time 1 1 2 
                   Most of the time 3 1 4 
                   A good bit of the time 1  1 
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                   Some of the time 1 1 2 
                   A little of the time 5 4 9 
                   None of the time 3 4 7 
Did you feel tired?    
                 All of the time 4 1 5 
                   Most of the time 3 4 7 
                   A good bit of the time 3 3 6 
                   Some of the time 2 2 4 
                   A little of the time 2 1 3 
During the past 4 weeks, how much of the time has your physical 
health or emotional  
problems interfered with your social activities (like visiting with 
friends, relatives, etc.)?                    
   
                 All of the time 4 4 8 
                   Most of the time 6 4 10 
                   Some of the time 3 2 5 
                   A little of the time  1 1 
                   None of the time 1  1 
seem to get sick a little easier than other people?    
                   Definitely true 3 3 6 
                    Mostly true 2 4 6 
                  Don’t know 5  5 
                    Mostly false 4 2 6 
                    Definitely false  2 2 
I am as healthy as anybody I know?    
                   Definitely true 1  1 
                  Don’t know 2  2 
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                    Mostly false 8 7 15 
                    Definitely false 3 4 7 
I expect my health to get worse?    
                   Definitely true 1 2 3 
                    Mostly true 1 3 4 
                  Don’t know 7 5 12 
                    Mostly false 3  3 
                    Definitely false 2 1 3 
My health is excellent?    
                    Mostly true  1 1 
                  Don’t know 3 1 4 
                    Mostly false 8 5 13 
                    Definitely false 3 4 7 
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Appendix 4: Patient and clinical data sheet 
Name                    
Age                         
Educational Level 
Not at school 
 
Primary 
school 
Secondary School More 
Sex                                      Male    Female    
Age at which Thalassemia was 
diagnosed 
< 1  year 1 -3 years                   3-5 years    > 5 years 
Consanguineous marriage of the parents Yes                             No                
Siblings status of thalassemia  
 
Yes                              
 
No               
    
 
Family history of thalassemia  
 
Yes                              
 
No                
                     
              
 
Family history of any other blood diseases like (sickle cell 
anemia , G6PD deficiency anemia, hemophilia) 
 
Yes                            
 
No               
   
Types of 
Thalassaemia 
 
 
Rate of Blood transfusion /year 
 
<12 
 
12 – 24 
 
>24 
 
 
Hemoglobin level at the time of 
transfusion  
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Number of times patient should get chelation 
(desferroxamine)/month 
 
 
<5 
 
6 – 10 
 
11-15 
 
 
Splenectomy ( removal of the spleen) 
 
Yes                                
 
No              
   
 
Effectiveness of splenectomy in reducing blood 
transfusion  
 
Yes                                 
 
No             
  
Laboratory Investigations: 
 
Pre transfusion Hemoglobin level: 
Serum Ferritin: 
MCV 
Hemoglobin Electrophoresis: 
Rate of blood transfusion: 
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Appendix 5: SF-36 questionnaire  
 In general, would you say your health?                                              
 Compared to one year, how would you rate your health in general now? : 
3- The following items are about activities you might do during a typical day.  Does your health 
now limit you in these activities? If so, how much? 
Activities 1. Yes,  
Limited A 
Lot 
2.  Yes, 
Limited A 
Little 
3.  No,  
Not Limited  At 
All 
a) Vigorous activities, such as running, 
lifting heavy objects, participating in 
strenuous sports? 
   
b) Moderate activities, such as moving a 
table, pushing a vacuum cleaner, bowling, or 
playing golf? 
   
c) Lifting or carrying groceries?    
d) Climbing several flights of stairs?    
e) Climbing one flight of stairs?    
f) Bending, kneeing or stooping?    
g) Walking more than a mile?    
h) Walking several blocks?    
i) Walking one block?    
j) Bathing or dressing yourself?    
4-During the past 4 weeks, have you had any of the following problems with your work, school, 
or other regular activities as a result of your physical health 
   1. 
yes 
  2. 
No 
Excellent  Very good  Good  Fair   Poor  
1 2 3 4 5 
Much better 
now than one 
year ago 
Somewhat better 
now than one 
year ago 
About the 
same 
Somewhat worse now 
than one year ago 
Much worse now 
than one year 
ago. 
1 2 3 4 5 
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a) Cut down on the amount of time you spent on work/school or other 
activities? 
 
  
b) Accomplished less than you would like? 
 
  
c) Were limited in the kind of work or other activities? 
 
  
d) Had difficulty performing the work, school or other activities (for 
example it took extra effort)? 
 
  
5-During the past 4 weeks, have you had any of the following problems with your work or other 
regular daily activities as a result of any emotional problems (such as feeling depressed or 
anxious)? 
   1. 
yes 
  2. 
No 
a) Cut down on the amount of time you spent on work/school or other 
activities? 
  
b) Accomplished less than you would like?   
d) Didn’t do work or other activities as carefully as usual?   
6- During the past 4 weeks, to what extent has your physical health or emotional problems 
interfered with your normal social activities with family, friends, neighbors, or groups? 
7.How much bodily pain have you had during the past 4 weeks? 
 
8- During the past 4 weeks, how much did pain interfere with your normal work (including both 
work outside the home and housework)? 
          
Not at all  Slightly  Moderately Quite a bit Extremely  
1 2 3 4 5 
None   Very mild Mild   Moderate  Severe  Very sever 
1 2 3 4 5 6 
Not at 
all  
Slightly  Moderately  Quite a bit  Extremely  
1 2 3 4 5 
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9- These questions are about how you feel and how things have been with you during the past 4 
weeks.  For each question, please give the one answer that comes closest to the way you have 
been feeling.  How much of the time during the past 4 week. 
 1. All of 
the time 
2. Most 
of the 
time 
3. A good 
bit of the 
time 
 
4. Some 
of the 
timeا 
5. A 
little of 
the 
time 
6. None 
of the 
time 
 
a) Did you feel full of 
pep? 
      
b) Have you been a very 
nervous person? 
      
c) Have you felt so down 
in the dumps that nothing 
could cheer you up?  
      
d) Have you felt calm and 
peaceful? 
      
e) Did you have a lot of 
energy? 
      
f) Have you felt 
downhearted and blue? 
      
g) Do you feel worn out?       
h) Have you been a happy 
person? 
      
i) Did you feel tired?       
 
10- During the past 4 weeks, how much of the time has your physical health or emotional 
problems interfered with your social activities (like visiting with friends, relatives, etc.)? 
 
 
 
All of the time Most of the time. Some of the 
time 
A little of the 
time. 
None of the 
time. 
1 2 3 4 5 
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11. How TRUE or FALSE is each of the following statements for you? 
 1. Definitely 
true 
2. 
Mostly 
true 
3. Don’t 
know 
4. 
Mostly 
false 
5. 
Definitely 
false 
a) I seem to get sick a little 
easier than other people? 
 
     
b) I am as healthy as 
anybody I know? 
     
c) I expect my health to get 
worse? 
     
d) My health is excellent?      
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 Appendix 6: Arabic version of the questionnaire 
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Appendix 7: Charts showing a comparison of the quality of life domains between 
patients in the former study of 2011 and the current 2014 study: 
A. PF is nearly the same in the two studies. 
 
B. RP is higher in the current study than the former study. RP showed the highest 
difference between the two studies 
 
 
C. BP is higher in the current study than the former study. 
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D. GH is higher in the current study than the former study. 
 
 
 
E. VT is higher in the current study than the former study. 
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F. SF is higher in the current study than the former study. 
 
 
 
G. RE is higher in the current study than the former study. 
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H. MH is higher in the current study than the former study. 
 
 
I. PCS is higher in the current study than the former study. 
94 
 
 
J. MCS is higher in the current study than the former study. 
 
 
 
 
